title: [The preliminary results of a phase II randomized clinical trial of high-dose toremifene chemosensitization in stage IIIB/IV non-small cell lung cancer].
abstract: BACKGROUND
  To investigate whether high-dose toremifene can enhance the efficacy of chemotherapy in non small cell lung cancer.
  
  
  METHODS
  Untreated stage IIIB/IV non-small cell lung cancer patients were randomly devided into group A (high-dose toremifene combined with the platinum-based chemotherapy) or group B (the same platinum-based chemotherapy alone).
  
  
  RESULTS
  A total of 30 eligible patients had been recruited. Hemotologic and nonhemotologic toxicities were similar with no statistic difference. The median survival for group A was 8 months, 95% CI (6.63-9.37) versus 7.5 months, 95% CI (4.75-10.25) for group B ( P =0.9). One year-survival rate was 31% for group A versus 28% for group B ( P =0.87). The response rate was 25% for group A versus 21% for group B ( P =0.99).
  
  
  CONCLUSIONS
  The results suggest that high-dose toremifene does not enhance the efficacy of platinum-based chemotherapy for IIIB/IV non-small cell lung cancer but toxicities are well tolerated.
authors.affiliation: Department of Thoracocardiac Disease, The 5th University Hospital, Sun Yat sen University, Zhuhai, Guangdong 519000, P.R.China.
authors.forename: Hua
authors.initials: H
authors.lastname: Cheng
authors.forename: Yilong
authors.initials: Y
authors.lastname: Wu
authors.forename: Lijia
authors.initials: L
authors.lastname: Gu
authors.forename: Weineng
authors.initials: W
authors.lastname: Feng
authors.forename: Yimin
authors.initials: Y
authors.lastname: Weng
authors.forename: Chao
authors.initials: C
authors.lastname: Cheng
authors.forename: Wenzhao
authors.initials: W
authors.lastname: Zhong
authors.forename: Shaohong
authors.initials: S
authors.lastname: Huang